Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients
DC Chan, SJ Hamilton, KA Rye, GT Chew, AJ Jenkins, G Lambert, GF Watts
DIABETES OBESITY & METABOLISM | WILEY-BLACKWELL | Published : 2010
AIM: Diabetic dyslipidaemia, characterized by hypertriglyceridaemia as a result of elevated serum very-low-density lipoprotein (VLDL) concentrations, contributes to the increased risk of cardiovascular disease (CVD) in type 2 diabetes (T2DM). Proprotein convertase subtilisin/kexin type 9 (PCSK9) may play a role in regulating VLDL metabolism. We investigated the effect of fenofibrate on serum PCSK9 and VLDL particle concentrations in T2DM patients already receiving statin therapy. METHODS: In a double-blind randomized crossover study, 15 statin-treated T2DM patients (63 +/- 8 years, body mass index (BMI) 29 +/- 3 kg/m(2)) were treated with fenofibrate (145 mg/day) or matching placebo for 12 w..View full abstract
Awarded by NHF
D.C. Chan is a Career Development Fellow of the National Health and Medical Research Council (NHMRC). S. J. Hamilton received a postgraduate scholarship from the NHMRC. This work was also supported by an NHF grant in aid G08S3700 to G. Lambert and K. A. Rye. Wethank Solvay for supplying the fenofibrate and matching placebo for the study.